Asthmanefrin Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Asthmanefrin Supply and Availability in 2026

Patients are increasingly asking their healthcare providers about Asthmanefrin (Racepinephrine Hydrochloride 2.25%), the over-the-counter bronchodilator marketed by Nephron Pharmaceuticals. Some patients rely on it because they lack insurance or regular access to a prescriber. Others have been using it for years as a convenient, no-prescription-needed rescue option.

This article provides a clinical overview of the current Asthmanefrin supply situation, its implications for your practice, and the tools available to help patients who are struggling to find this product.

Product Overview

Asthmanefrin is an OTC adrenergic bronchodilator containing Racepinephrine Hydrochloride 2.25% (equivalent to approximately 1% epinephrine) in 0.5 mL single-use vials. It is administered via the EZ Breathe Atomizer, a hand-held bulb nebulizer included with the Starter Kit.

Key clinical details:

• Indication: Temporary relief of mild symptoms of intermittent asthma (wheezing, chest tightness, dyspnea)
• Dosing: 1-3 inhalations every 3 hours as needed; maximum 12 inhalations per 24 hours
• Age range: Adults and children 4 years and older
• Onset: Symptom improvement expected within 20 minutes
• Mechanism: Non-selective adrenergic agonist (alpha and beta receptor stimulation)
• Not a controlled substance

It is important to note that Asthmanefrin is intended for mild, intermittent symptoms only. Patients using it more than twice per week or requiring more than 9 inhalations in 24 hours for 3+ days per week may have undertreated persistent asthma requiring step-up therapy.

Supply Timeline and Current Status

Asthmanefrin was launched in August 2012 by Nephron Pharmaceuticals as an OTC alternative to the discontinued Primatene Mist CFC inhaler. Key timeline points:

• 2012: Product launch, available nationally at Walmart, CVS, and other retailers
• 2018: Primatene Mist returns to market with an HFA formulation, creating competition in the OTC asthma space
• 2020-2023: Pandemic-era supply chain disruptions affect pharmaceutical manufacturing broadly; Racepinephrine inhalation solution appears on ASHP shortage list
• 2024-2025: Intermittent retail availability continues; patients report significant price increases on refill packs
• 2026 (current): Not listed on FDA drug shortage database; manufacturer continues production; retail availability remains inconsistent

Prescribing Implications

While Asthmanefrin does not require a prescription, its availability issues have clinical implications that providers should be aware of:

Patients May Be Undertreated

Patients who rely exclusively on OTC products like Asthmanefrin for asthma management may not be receiving guideline-concordant care. If a patient reports difficulty finding Asthmanefrin, it's an opportunity to:

• Confirm the asthma diagnosis and assess severity
• Evaluate whether the patient needs a controller medication (inhaled corticosteroid)
• Prescribe a selective beta-2 agonist rescue inhaler (Albuterol) with better efficacy and safety profile

Non-Selective Adrenergic Stimulation

Racepinephrine's non-selective mechanism means it stimulates alpha-1, beta-1, and beta-2 receptors. Compared to Albuterol (selective beta-2), this carries greater cardiovascular risk, including:

• Hypertension
• Tachycardia
• Increased myocardial oxygen demand
• Potential QTc prolongation (interaction with certain medications)

For patients with comorbid cardiovascular disease, hypertension, diabetes, thyroid disorders, or those taking MAO inhibitors, Asthmanefrin is not an appropriate choice.

Drug Interactions

The most critical interaction is with MAO inhibitors — Asthmanefrin is contraindicated within 14 days of MAO inhibitor use. Other interactions of clinical concern include:

• Other sympathomimetic agents (additive cardiovascular effects)
• Tricyclic antidepressants (potentiation of pressor effect)
• Beta-blockers (antagonism of bronchodilatory effect)
• QTc-prolonging medications (arsenic trioxide, artemether/lumefantrine, certain antiarrhythmics)

For a comprehensive reference, see our article on Asthmanefrin drug interactions.

Current Availability Picture

As of early 2026:

• Manufacturer: Nephron Pharmaceuticals continues to produce Asthmanefrin and offers direct sales at asthmanefrin.com
• Retail: Intermittently available at Walmart, CVS, Walgreens, and Amazon; stock levels vary by location
• Pricing: Starter Kit $35-$50; 30-count Refill Pack $30-$75+; not covered by insurance but HSA/FSA eligible
• No generic equivalent: There is no OTC generic racepinephrine product. S2 Inhalant is a prescription-grade racepinephrine product used in clinical settings.

Cost and Access Considerations

One reason patients gravitate toward OTC products is cost and access. Important context for providers:

• Asthmanefrin requires no office visit, no insurance, and no prescription
• However, its current retail cost of $30-$75 for 30 vials may exceed the cost of generic Albuterol inhalers ($25-$50), especially with the recent $35 price caps on many branded inhalers
• Patients without insurance may benefit from a prescription with a discount card (GoodRx, SingleCare) for Albuterol, which can be as low as $15-$25

The cost advantage of OTC has narrowed significantly in 2026. Patients who previously avoided the healthcare system for cost reasons may now find prescription options more affordable.

Tools and Resources for Your Patients

If your patients are struggling to find Asthmanefrin or need help navigating their options:

• Medfinder for Providers: A free tool that helps locate hard-to-find medications at pharmacies. Share it with patients who are having trouble finding their medications.
• Asthmanefrin.com: The manufacturer's direct-order website, often available when retail is not
• NeedyMeds.org and RxAssist.org: Resources for patients who need help affording medications

Looking Ahead

The OTC asthma treatment landscape may continue to evolve. Key trends to watch:

• Potential Albuterol OTC switch: There has been ongoing discussion about making Albuterol available without a prescription, though this has not materialized as of 2026
• Continued inhaler price reforms: Federal and manufacturer-driven price caps are making prescription inhalers more accessible
• Single-source risk: As long as Nephron remains the sole manufacturer of OTC racepinephrine, supply interruptions will remain a possibility

Final Thoughts

Asthmanefrin's availability challenges present an opportunity for providers to engage patients about their asthma management. For many patients using OTC epinephrine products, a proper asthma evaluation and a prescription for a selective beta-2 agonist would represent a meaningful improvement in their care.

When patients ask about Asthmanefrin, consider it a conversation starter — not just about finding the product, but about whether their asthma is being optimally managed.

For more clinical resources, visit Medfinder for Providers. For patient-facing information, share our guides on what Asthmanefrin is and alternatives to Asthmanefrin.